MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

Search

Zentalis Pharmaceuticals Inc

Geschlossen

1.49 -3.87

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

1.48

Max

1.51

Schlüsselkennzahlen

By Trading Economics

Einkommen

21M

-27M

Gewinnspanne

-176.706

Angestellte

166

EBITDA

9.7M

-36M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+350.34% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

10. Nov. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

21M

121M

Vorheriger Eröffnungskurs

5.36

Vorheriger Schlusskurs

1.49

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

Zentalis Pharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

17. Okt. 2025, 18:13 UTC

Wichtige Markttreiber

Revolution Medicines Rises as FDA Grants Priority Designation for Cancer Treatment

17. Okt. 2025, 17:05 UTC

Wichtige Markttreiber

Artiva Biotherapeutics Shares Jump After Treatment Gets Fast Tracked

18. Okt. 2025, 13:30 UTC

Akquisitionen, Fusionen, Übernahmen

Deal Expected to Value Unit at Roughly $4B, Sources Say -- WSJ

18. Okt. 2025, 13:30 UTC

Akquisitionen, Fusionen, Übernahmen

Deal Could Be Announced as Soon as Next Week, Sources Say -- WSJ

18. Okt. 2025, 13:30 UTC

Akquisitionen, Fusionen, Übernahmen

Gucci Owner Kering Nears $4 Billion Sale of Beauty Unit to L'Oréal -- WSJ

18. Okt. 2025, 13:30 UTC

Akquisitionen, Fusionen, Übernahmen

Gucci Parent Kering in Talks to Sell Beauty Business to L'Oréal, Sources Say -- WSJ

18. Okt. 2025, 08:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

18. Okt. 2025, 07:00 UTC

Ergebnisse

A Growing Nimby Movement Could Upend the Data Center Boom -- Barrons.com

17. Okt. 2025, 23:25 UTC

Akquisitionen, Fusionen, Übernahmen

New Zealand's 'Golden Visa' Targets the Affluent in Search of Plan B -- Barrons.com

17. Okt. 2025, 22:15 UTC

Market Talk

Ulta's CFO Appointment Seen Supporting Growth -- Market Talk

17. Okt. 2025, 21:15 UTC

Market Talk

Greece Expected to Post Overall Budgetary Surplus This Year -- Market Talk

17. Okt. 2025, 21:07 UTC

Market Talk

Oracle Stock Expected to Take a Breather as Capex Climbs -- Market Talk

17. Okt. 2025, 21:07 UTC

Market Talk

Global Equities Roundup: Market Talk

17. Okt. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

17. Okt. 2025, 20:34 UTC

Market Talk

Deere Is Reaching the End of Its Downcycle -- Market Talk

17. Okt. 2025, 20:27 UTC

Market Talk

Soft Growth Ahead in Canada But Not Far Off From Potential GDP, Macklem Says -- Market Talk

17. Okt. 2025, 19:46 UTC

Market Talk

U.S. Natural Gas Futures Snap Losing Streak -- Market Talk

17. Okt. 2025, 19:45 UTC

Market Talk

Oil Futures Stabilize, But End Week With A Loss -- Market Talk

17. Okt. 2025, 18:45 UTC

Market Talk

Treasury Yields, Dollar Try to Reclaim Some Ground -- Market Talk

17. Okt. 2025, 17:51 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17. Okt. 2025, 17:51 UTC

Market Talk

Euro Still a Long Way From Supplanting Dollar, Former ECB Rate Setter Says -- Market Talk

17. Okt. 2025, 17:44 UTC

Market Talk

EQT Seen With Long-Term Growth Opportunities -- Market Talk

17. Okt. 2025, 17:35 UTC

Market Talk

U.S. Oil Rig Count Unchanged at 418 -- Market Talk

17. Okt. 2025, 16:20 UTC

Market Talk
Ergebnisse

Tech, Media & Telecom Roundup: Market Talk

17. Okt. 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

17. Okt. 2025, 16:14 UTC

Market Talk

Home Depot Will Gain From Pick Up in Home Improvement Activity -- Market Talk

17. Okt. 2025, 16:04 UTC

Market Talk

Home Improvement Demand Is Starting to Pick Up -- Market Talk

17. Okt. 2025, 15:58 UTC

Market Talk

Amazon's Project Rainier Will Begin to Stem Its AI Share Losses -- Market Talk

17. Okt. 2025, 15:56 UTC

Ergebnisse

These Stocks Are Moving the Most Today: Zions Bancorp, Jefferies, Amex, Oracle, Novo Nordisk, Lilly, State Street, CSX, and More -- Barrons.com

17. Okt. 2025, 15:43 UTC

Market Talk

Global Equities Roundup: Market Talk

Peer-Vergleich

Kursveränderung

Zentalis Pharmaceuticals Inc Prognose

Kursziel

By TipRanks

350.34% Vorteil

12-Monats-Prognose

Durchschnitt 6.71 USD  350.34%

Hoch 10 USD

Tief 4 USD

Basierend auf 8 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Zentalis Pharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

8 ratings

4

Buy

4

Halten

0

Sell

Technischer Score

By Trading Central

1.23 / 1.45Unterstützung & Widerstand

Kurzfristig

Very Strong Bearish Evidence

Mittelfristig

Weak Bullish Evidence

Langfristig

Weak Bearish Evidence

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.
help-icon Live chat